Rapid laboratory assessment of heparin-induced thrombocytopenia (HIT) is important for
disease recognition and management. The utility of contemporary immunoassays to detect …

Essentials• Many patients produce antibodies but few lead to heparin‐induced
thrombocytopenia (HIT).• Pathogenic epitopes are difficult to identify as HIT antibodies are …

Laboratory testing for heparin-induced thrombocytopenia (HIT) has important shortcomings.
Immunoassays fail to discriminate platelet-activating from nonpathogenic antibodies …

Heparin-induced thrombocytopenia/thrombosis (HIT/T) is a common complication of heparin
therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin. The …

Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallmark of heparin-
induced thrombocytopenia and thrombosis (HIT), but many antibody-positive patients have …

Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that
recognize PF4/heparin complexes. Uncertainties remain regarding HIT immunobiology …

Antibodies to PF4/heparin can be demonstrated in almost all patients with heparin-induced
thrombocytopenia/thrombosis (HIT/HITT) and in some persons exposed to heparin who do …

Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating anti–platelet factor
4 (PF4)/heparin antibodies. Platelet activation assays that use “washed” platelets are more …

Essentials• No humanized monoclonal antibody was available to study heparin‐induced
thrombocytopenia (HIT).• We developed the first anti‐platelet factor 4 (PF4)/heparin antibody …

Background Heparin-induced thrombocytopenia (HIT) is typically caused by platelet-
activating immunoglobulin G (IgG) antibodies (Abs) against platelet factor 4 (PF4) …